All the Active Ingredient Drugs
Interleukin Inhibitor, Monoclonal Antibody. Risankizumab 150 mg. Pre-fil. syr/pen with sol. for SC inj. with 150 mg
For mod. to sev. plaque psor. in adlts. who are candidates for syst. ther. Alone or in comb. with methotrexate (MTX) for act. psoriatic arthr. in adlts who had an inadeq. resp.or who have intol. to one or more dis.-modifying antirheum. drugs (DMARDs). Recom. dose 150 mg admin. at week 0, week 4, and every 12 weeks thereafter one 150 mg pre-filled pen or pre-filled syr. inject).
C/I: Hypersens. Clinic. import. act. infect. (e.g. act.TB)
Interleukin Inhibitor, Monoclonal Antibody. Risankizumab 180 mg, 360 mg, 600 mg. Cartr. Sol. for inj. 1 X 180/360 mg
Vial. Conc. for sol. for inf. 1 X 600 mg/10 ml
For Chron dis.: 600 mg by IV inf. at week 0, week 4, and week 8, followed by 360 mg by SC inject. at week 12, and every 8 weeks thereafter.
For Ulcer. col.: induction dose 1200 mg by IV inf. at week 0, week 4, and week 8. Starting at week 12 and every 8 weeks thereafter, maint. dose is based on individual ptt. presentation.
360 mg and 600 mg: Crohn’s disease in pts > 16 years with mod. to sev. active CD who have had an inadequate response to, lost response to, or were intol. to conventional ther. or a biologic ther., or if such ther. are not advisable.
180, 360 mg and 600 mg: Ulcerative colitis in adults with mod. to sev. active UC who have had an inadequate response to, lost response to, or were intol. to conventional ther. or a biologic ther.
C/I: Hypersens./Clin. important active infect. (e.g. active TB).
